Orthofix Medical Inc. OFIX R2KR3KPHARMA
Company Overview
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $822.31M (+2.9% YoY); net profit $-92.19M.
- Trailing 12 Months Year-on-year growth — revenue +3.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.60% |
| 1 Year: | 3.80% |
Stock Price Performance
| 1 Year: | -34.12% |
| 6 Months: | -20.57% |
| 3 Months: | -17.56% |
| 1 Month: | +7.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.55 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 39.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OFIX Orthofix Medical Inc. R2KR3KPHARMA | 9.81 | -6.45 | $399.59M | 0.00% | -11.97% | -13.91% | 2.60% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 102.74M | 108.94M | 105.25M | 116.90M | 108.71M | 111.55M | 111.71M | 121.08M | 109.11M | 115.85M | 113.50M | 121.49M | 104.82M | 73.14M | 110.98M | 105.59M | 121.39M | 112.43M | 106.42M | 118.07M | 114.00M | 175.20M | 187.02M | 184.01M | 188.61M | 198.62M | 196.61M | 193.65M | 203.12M | 205.63M | 196.71M | 210.93M |
| Gross Profit | 70.42M | 79.04M | 77.29M | 83.21M | 76.54M | 81.56M | 78.62M | 85.22M | 80.16M | 85.77M | 81.53M | 93.33M | 84.56M | 88.71M | 87.69M | 95.45M | 85.40M | 90.04M | 88.60M | 95.30M | 81.41M | 49.97M | 84.74M | 79.68M | 93.95M | 84.12M | 78.10M | 86.47M | 83.42M | 110.33M | 119.55M | 119.76M | 127.24M | 134.75M | 135.05M | 121.62M | 139.53M | 148.52M | 139.55M | 149.71M |
| Operating Income | -7.19M | 4.93M | 4.14M | 7.38M | 7.08M | -2.69M | 9.27M | 7.42M | 5.92M | 8.00M | 9.03M | 17.86M | 7.87M | 5.92M | 3.91M | 12.40M | -4.45M | 451.00K | -18.88M | 4.09M | 6.85M | -21.00M | 4.17M | -2.92M | 4.27M | -313.00K | -3.08M | 6.64M | -5.79M | -59.71M | -36.63M | -24.45M | -29.34M | -24.91M | -18.90M | -48.87M | -16.00M | -17.05M | -14.44M | -8.13M |
| Net Income | -8.38M | 3.57M | -1.37M | 3.37M | 3.84M | -7.44M | 9.90M | -3.24M | -2.65M | 3.85M | 3.46M | 1.57M | 5.23M | 925.00K | -1.21M | 8.87M | 897.00K | -547.00K | -40.50M | 11.69M | 25.66M | -18.42M | 4.65M | -5.82M | 2.42M | -2.17M | -4.46M | 2.49M | -10.72M | -60.94M | -39.43M | -28.86M | -36.02M | -33.44M | -27.39M | -53.09M | -14.08M | -22.80M | -20.91M | -15.80M |
| Diluted EPS | -0.45 | 0.19 | -0.07 | 0.18 | 0.20 | -0.41 | 0.54 | -0.18 | -0.15 | 0.21 | 0.19 | 0.08 | 0.27 | 0.05 | -0.07 | 0.46 | 0.05 | -0.03 | -2.14 | 0.60 | 1.32 | -0.96 | 0.24 | -0.30 | 0.12 | 0.11 | -0.22 | 0.12 | -0.53 | -1.71 | -1.07 | -0.77 | -0.95 | -0.88 | -0.71 | -1.35 | -0.36 | -0.57 | -0.52 | -0.39 |
| R&D Expense | 5.84M | 6.45M | 6.52M | - | 7.64M | 6.80M | 6.86M | - | 7.42M | 6.89M | 6.93M | - | 6.94M | 7.89M | 9.60M | - | 9.23M | 8.98M | 7.98M | - | 9.96M | 8.77M | 9.96M | 10.90M | 13.12M | 12.36M | 11.21M | 12.76M | 11.94M | 23.31M | 19.42M | 18.56M | 19.49M | 18.05M | 17.29M | 19.77M | 15.93M | 14.77M | 15.32M | 15.94M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 545.63M | 460.63M | 441.97M | 440.19M | 397.61M | 402.28M | 396.49M | 409.79M | 433.82M | 453.04M | 459.95M | 406.56M | 464.48M | 460.71M | 746.64M | 799.49M | 822.31M |
| Gross Profit | 407.19M | 370.17M | 346.44M | 339.46M | 290.70M | 303.37M | 309.96M | 321.94M | 340.79M | 356.41M | 359.35M | 304.67M | 349.56M | 337.17M | 486.27M | 545.88M | 566.02M |
| Operating Income | 63.88M | 66.25M | 5.90M | 74.87M | -11.19M | 17.14M | 9.26M | 21.07M | 40.81M | 30.09M | -18.78M | -6.27M | -8.31M | -13.27M | -139.11M | -84.62M | -81.43M |
| Net Income | 24.47M | 44.21M | -18.11M | 42.85M | -28.81M | -8.54M | -2.81M | 3.06M | 6.22M | 13.81M | -28.46M | 2.52M | -38.38M | -19.75M | -151.40M | -126.00M | -92.19M |
| Diluted EPS | 1.42 | 2.47 | -0.99 | 2.21 | -1.54 | -0.46 | -0.15 | 0.17 | 0.34 | 0.72 | -1.51 | 0.13 | -1.95 | -0.98 | -4.12 | -3.30 | -2.33 |
| R&D Expense | 31.46M | 27.96M | 22.86M | 28.58M | 26.77M | 24.99M | 26.39M | 28.80M | 29.70M | 33.22M | 34.64M | 39.06M | 49.62M | 49.06M | 80.23M | 73.64M | 65.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Mar 2012 | Jun 2012 | Sep 2012 | Dec 2012 | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 603.99M | 704.47M | 694.11M | 530.39M | 539.57M | 472.90M | 464.15M | 446.32M | 415.52M | 411.98M | 403.97M | 434.00M | 411.05M | 392.96M | 400.22M | 372.10M | 405.35M | 466.64M | 495.62M | 525.86M | 476.62M | 458.63M | 925.32M | 893.29M | 850.65M |
| Total Equity | 202.06M | 240.27M | 300.89M | 292.07M | 312.37M | 325.20M | 345.97M | 356.44M | 360.98M | 332.15M | 306.99M | 295.86M | 300.56M | 305.21M | 305.02M | 299.63M | 290.31M | 263.48M | 296.61M | 335.40M | 327.63M | 356.86M | 336.93M | 336.86M | 598.73M | 503.12M | 450.04M |
| Cash & Equivalents | 14.59M | 13.33M | 13.56M | 32.74M | - | - | - | 30.77M | - | - | - | 28.92M | - | - | - | 36.81M | 63.66M | 39.57M | 81.16M | 69.62M | 69.72M | 96.29M | 87.85M | 50.70M | 33.11M | 83.24M | 82.03M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - | - | - | - | - | 93.11M | 157.01M | 157.39M |
| Total Liabilities | - | - | 303.10M | 389.30M | 381.73M | 205.20M | 193.60M | 105.06M | 103.18M | 114.17M | 108.53M | 116.11M | 103.41M | 128.79M | 106.03M | 93.33M | 109.91M | 108.63M | 108.75M | 131.24M | 167.99M | 169.00M | 139.69M | 121.77M | 326.58M | 390.17M | 400.61M |
| Current Liabilities | - | - | 83.53M | 185.81M | - | - | - | 62.19M | - | - | - | 70.35M | - | - | - | 66.44M | 81.99M | 83.44M | 79.41M | 85.91M | 84.88M | 103.90M | 105.83M | 83.62M | 165.22M | 168.63M | 170.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | 67.04M | 51.16M | 43.61M | 59.08M | 38.97M | 49.92M | 32.03M | 74.27M | 18.48M | -11.54M | -45.75M | 25.79M | 33.35M |
| Investing Cash Flow | -22.29M | -2.15M | -31.01M | - | -31.05M | -19.95M | -38.35M | -21.95M | -16.47M | -61.00M | -22.92M | -52.33M | -23.01M | -24.53M | -33.13M | -27.58M | -34.60M |
| Financing Cash Flow | -29.95M | -40.03M | -13.66M | - | -38.35M | -20.20M | 24.73M | -46.11M | 3.54M | 2.99M | -10.69M | 3.25M | -3.62M | -78.00K | 65.32M | 50.71M | -786.00K |
| Capital Expenditure | -20.91M | -25.84M | -24.96M | -27.99M | -24.79M | -18.07M | -27.20M | -16.43M | -14.66M | -13.59M | -19.00M | -15.48M | -17.79M | -21.36M | -60.26M | - | - |
| Free Cash Flow | - | - | - | - | 42.26M | 33.09M | 16.41M | 42.64M | 24.31M | 36.33M | 13.04M | 58.79M | 690.00K | -32.90M | -106.01M | - | - |
| Share Buybacks | - | - | - | - | 39.49M | - | 11.57M | 63.42M | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 74.6% | 80.4% | 78.4% | 77.1% | 73.1% | 75.4% | 78.2% | 78.6% | 78.6% | 78.7% | 78.1% | 74.9% | 75.3% | 73.2% | 65.1% | 68.3% | 68.8% |
| Operating Margin % | 11.7% | 14.4% | 1.3% | 17.0% | -2.8% | 4.3% | 2.3% | 5.1% | 9.4% | 6.6% | -4.1% | -1.5% | -1.8% | -2.9% | -18.6% | -10.6% | -9.9% |
| Net Margin % | 4.5% | 9.6% | -4.1% | 9.7% | -7.2% | -2.1% | -0.7% | 0.7% | 1.4% | 3.0% | -6.2% | 0.6% | -8.3% | -4.3% | -20.3% | -15.8% | -11.2% |
| ROE % | 10.2% | 14.7% | -6.2% | 12.0% | -9.7% | -2.8% | -1.0% | 1.2% | 2.1% | 4.1% | -8.7% | 0.7% | -11.4% | -5.9% | -25.3% | -25.0% | -20.5% |
| ROCE % | - | 12.7% | 1.1% | 18.2% | -3.3% | 5.2% | 2.9% | 7.3% | 12.5% | 7.9% | -4.6% | -1.5% | -2.2% | -3.5% | -18.3% | -11.7% | -12.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Engine Capital Management, LP | 11.23% | 4.58M | $41.96M |
| 2 | Juniper Investment Company, LLC | 10.91% | 4.44M | $40.74M |
| 3 | Rubric Capital Management LP | 9.14% | 3.72M | $34.13M |
| 4 | Blackrock Inc. | 8.17% | 3.33M | $30.50M |
| 5 | Paradigm Capital Management | 8.10% | 3.30M | $30.27M |
| 6 | Armistice Capital, LLC | 8.01% | 3.26M | $29.93M |
| 7 | Vanguard Capital Management LLC | 4.25% | 1.73M | $15.87M |
| 8 | Geode Capital Management, LLC | 2.57% | 1.05M | $9.61M |
| 9 | State Street Corporation | 2.34% | 953.15K | $8.74M |
| 10 | AQR Capital Management, LLC | 2.18% | 887.28K | $8.14M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OFIX
Orthofix Medical (OFIX) Stock Sees Fair Value Cut After Analysts Trim Q2 Outlook - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNWTJkRnBPQlBuSUdoaVhaSGpRN3FzQkdCYzlReWhqdFFRb3dnamItdVFqQlRrZk5jYzZESU56MElfTHpfb1pSV2p5VjExLVFPWEJGSEZyYVVqRDRwWmR4V1I1VXFGZGZTOWlIZ01naGM4aS1ldjI0NFZrWWVVQUpMWGdkeHZlanZHYlBmSG…
Orthofix to Report Third Quarter 2026 Financial Results - www.marketscreener.com
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPUmlHLU95SURwbVdYNENRWGpRajZCaUViMDZBUGVGT0xGdGs1ZWxaNV81RGVmOUlxcDV0RHJTZmFscTJ2Q1ZvSkQ1VzZKTzBKNEtPLWVwVW9fVUZIdTRxdmVUd201OFBtVmRNdlVTTnRMdWowZ0VERU5wT2h1a3F1cEJWZ1h2Q3FHSVRYYV…
OFIX Feb 2027 17.500 call (OFIX270219C00017500) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5RWEN4OVUzYm5LNEo1ajU2QmwyeWhRamZJVnNXNVdhdHdvTzdQV3puRlZqaHJhVU1VTm4zUDd3WmlhYWhqOVJaaXROOGVGX3IzMDRJVm5oOWc0dTFwQkV6WXljWW12UQ?oc=5" target="_blank">OFIX Feb 2027 17.500 call (OF…
Orthofix Medical (OFIX) Stock Sinks As One Off Growth Clouds Outlook - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOd09NZkVSbXU3NVFnX2tkSVAzcUxOQjVOVXhBNmxvc0o3dGxCWTQ4VFlzd3hsUjB2VmtYZm9NME1mMVJqNTl0blhrUE1lSEx6UDhjRk1vMmRKNl9NT09IOG9BUEZjSmVSUndMM2prcUV2UHp1d3B5UFpjTmE4a3U4UnF4SlJOdWVuOGh6dX…
OFIX 260918 17.50P (OFIX260918P17500) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMi7gJBVV95cUxObGdDSXdKSlBWSHlKVUVGamdlYU9jMnRwd1dBM09nSEhSc005dlZJMVdQdkF3RDJrendFLWJFaG9KM1pPaXdVQ2hRUDB3OFJ4aGtCX3JUN0lvbVh5NlBJNzRBbkhRZk9PYXk1QzF5MlMyUmJvTHBfRkszekxkRnludkhlWVZvOWk2VFpPbW…
Orthofix Medical drops despite Q2 beats - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPT0dRVDQycTYtUS01Z2FlRVpxTk5JU0dTYUtnY2pSVG1GLUpJVFFQdEtmS295VVZVMHM0UnlQbS1XLTNZWUlBRWI1QTNPWEQ1dXVKT0xpRjYydl85TUYzd1plZ3JidGhYM3pVZmlwQjdLUlotdkVrUGZfaEhSRlpQTDVLcw?oc=5" targe…
OFIX — Frequently Asked Questions
What is the current share price of Orthofix Medical Inc. (OFIX)?
As of 2026-10-23 16:27 PDT, Orthofix Medical Inc. (OFIX) trades at $9.81 on NasdaqGS. Its 52-week range is $8.64 to $16.23.
What is the market capitalisation of OFIX?
Orthofix Medical Inc. (OFIX) has a market capitalisation of $399.59M on NasdaqGS.
What is the P/E ratio of OFIX?
OFIX trades at a trailing price-to-earnings (P/E) ratio of -6.45. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.83.
What is the return on equity (ROE) of OFIX?
OFIX has a return on equity (ROE) of -13.91%. Its return on capital employed (ROCE) is -11.97%.
Is OFIX a good stock to buy?
This page provides a data-driven analysis of Orthofix Medical Inc. (OFIX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.